Articles dans des revues avec comité de lecture (179)
  1. 71. Foster, G. R., Heo, J., Kumada, H., Lu, S. N., Marcellin, P., Moreno, C., Roberts, S. K. E. S., Strasser, S., Thompson, A. J. V. A., Toyota, J., Paik, S. W., Chayama, K., Vierling, J. J., Zignego, A. L., Cohen, D., McPhee, F., Wind-Rotolo, M., Srinivasan, S., Hruska, M., Myler, H., Portsmouth, S. S., Chuang, W. L., Fainboim, H., Färkkilä, M., Gadano, A., Gaeta, G. B. A. G., Hezode, C., & Inada, Y. (2016). A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. SpringerPlus, 5(1), 1365. doi:10.1186/s40064-016-2920-z
  2. 72. Coilly, A., Leroy, V., Canva, V., Lebray, P., Moreno, C., Dumortier, J., Silvain, C., Besch, C., Perre, P., Botta-Fridlund, D., Anty, R., Fougerou-Leurent, C., Francoz, C., Abergel, A., Debette-Gratien, M., Conti, F., Habersetzer, F., Rohel, A., Rossignol, E., Danjou, H., Roque-Afonso, A. M., Samuel, D., De Ledinghen, V., Duclos-Vallée, J.-C., Pageaux, G.-P., Houssel-Debry, P., Duvoux, C., Di Martino, V., Radenne, S., Kamar, N., & D'Alteroche, L. (2016). Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study. Journal of hepatology, 65(4), 711-718. doi:10.1016/j.jhep.2016.05.039
  3. 73. Dumortier, J., Canva, V., Di Martino, V., Conti, F., Kamar, N., Moreno, C., Lebray, P., Tran, A., Besch, C., Diallo, M. A., Rohel, A., Leroy, V., Rossignol, E., Abergel, A., Botta-Fridlund, D., Coilly, A., Samuel, D., Duclos-Vallée, J.-C., Pageaux, G.-P., Duvoux, C., De Ledinghen, V., Francoz, C., Houssel-Debry, P., Radenne, S., D'Alteroche, L., & Fougerou-Leurent, C. (2016). Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver transplantation, 22(10), 1367-1378. doi:10.1002/lt.24505
  4. 74. Vandenbulcke, H., Delwaide, J., Orlent, H., Lasser, L., Trepo, E., Van Vlierberghe, H., Michielsen, P., Van Gossum, M., De Vos, M.-J., Marot, A., Doerig, C., Moreno, C., Henrion, J., Deltenre, P., Colle, I., Knebel, J. F., Francque, S., Serste, T., George, C., De Galocsy, C., & Laleman, W. (2016). Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. Journal of hepatology, 65(3), 543-551. doi:10.1016/j.jhep.2016.04.031
  5. 75. Moreno, C., & Domngang, D. (2016). Prise en charge de l'hépatite C chronique en 2016. Revue médicale de Bruxelles, 37(4), 283-288.
  6. 76. Asselah, T., Scott, J. T., Van Dooren, G., Lonjon-Domanec, I., Schlag, M., Buti, M., Moreno, C., Sarrazin, C., Gschwantler, M., Foster, G. R., Craxí, A., Buggisch, P., Ryan, R., & Lenz, O. (2016). An open-label trial of 12-week simeprevir plus Peginterferon/Ribavirin (PR) in treatment-naïve patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PloS one, 11(7), e0158526. doi:10.1371/journal.pone.0158526
  7. 77. Degré, D., Gustot, T., Gerkens, A., Boon, N., Schreiber, J., Lepida, A., Serste, T., Deltenre, P., Devière, J., Trepo, E., & Moreno, C. (2016). Insulin resistance is associated with esophageal varices in alcoholic liver disease patients. European journal of gastroenterology & hepatology, 28(7), 792-796. doi:10.1097/MEG.0000000000000627
  8. 78. Bourgeois, S., Van Damme, P., Van Vlierberghe, H., Vandijck, D., Moreno, C., Blach, S., Brixko, C., Laleman, W., Matheï, C., Mulkay, J.-P., Razavi, H., Robaeys, G., & Starkel, P. (2016). Achieving WHO recommendations for hepatitis C virus elimination in Belgium. Acta gastro-enterologica Belgica (Ed. multilingue), 79(2), 222-226.
  9. 79. Jensen, D. M., Ouzan, D., Wright, M., Morano, L. E., Buynak, R., Bourlière, M., Hassanein, T., Nishiguchi, S., Kao, J. H., Omata, M., Paik, S., Asselah, T., Wong, D., Tam, E., Kaita, K., Victor Feinman, S., Stern, J. J., Scherer, J., Quinson, A. M., Voss, F., Gallivan, J. P., Böcher, W. O., Dieterich, D., Ferenci, P., Foster, G. R., Sulkowski, M., Zeuzem, S., Mantry, P., Yoshida, E. E., & Moreno, C. (2016). Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: Pooled analysis of two phase 3 trials. Annals of Hepatology, 15(3), 333-349. doi:10.5604/16652681.1198803
  10. 80. Moreno, C., Deltenre, P., Senterre, C., Louvet, A., Gustot, T., Bastens, B., Hittelet, A.-B., Piquet, M.-A., Laleman, W., Orlent, H., Lasser, L., Serste, T., Starkel, P., De Koninck, X., Dastis, S. N., Delwaide, J., Colle, I., de Galocsy, C., Francque, S., Langlet, P., Putzeys, V., Reynaert, H., Degré, D., & Trepo, E. (2016). Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology, 150(4), 903-10.e8. doi:10.1053/j.gastro.2015.12.038
  11. 81. Feld, J. J., Reindollar, R. R., Larsen, L., Bolotin-Fukuhara, M., Howieson, K., Polepally, A. R., Pangerl, A., Shulman, N. N., Poordad, F., Moreno, C., Trinh, R., Tam, E., Bourgeois, S., Horsmans, Y., Elkhashab, M., Bernstein, D., & Younes, Z. (2016). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Journal of hepatology, 64(2), 301-307. doi:10.1016/j.jhep.2015.10.005
  12. 82. Schreiber, J., McNally, J., Chodavarapu, K., Svarovskaia, E., & Moreno, C. (2016). Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology, 64(3), 983-985. doi:10.1002/hep.28636
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Suivant >>